0354 GMT - The potential for US$50 million in cost synergies jumps out at UBS analysts as a key attraction of Telix Pharmaceuticals' US$2.35 billion acquisition of isotope manufacturer ITM. The analysts, who have a last-published buy rating on Telix's Australia-listed stock, tell clients in a note that the vertical integration of Telix with a supplier of key therapeutic isotopes strengthens its platform. They point out that ITM sits within a commercially validated category, with global annual sales of US$800 million for approved somatostatin receptor-targeted radioligand therapies. UBS has a target price of 22.00 Australian dollars on the stock, which is down 5.4% at A$16.88. (stuart.condie@wsj.com)

0345 GMT - The start of legal proceedings against Kingsgate by its political risk insurers "is yet another legal/regulatory issue which has unfortunately accompanied the stock at times," says MA Moelis Australia. The announcement doesn't suggest there will be any impact on current operations at the Chatree mine in Thailand, it says. However, "headlines like this (regardless of materiality) will remind investors that there are incremental complications to this business and jurisdiction," says MA. It has a buy rating and a target price of 6.45 Australian dollars on the stock. Shares are down 5.2% at A$5.12. (rhiannon.hoyle@wsj.com; @RhiannonHoyle)

0334 GMT - Telix Pharmaceuticals' US$2.35 billion acquisition of ITM gives the Australian company unparalleled exposure to the supply chain for cancer treatments' dominant therapeutic isotope, Bell Potter analyst John Hester says. Hester highlights to clients in a note ITM's position as a leading manufacturer of isotopes including 177Lu, which he points out is used in treatments including Novartis's Pluvicto. With margins on ITM's isotope production well in advance of TLX's margins on its manufacturing, his initial view is that the acquisition makes a lot of strategic sense. Bell Potter is reviewing its forecasts for Telix and its target price on the stock. Shares are down 5.1% at 16.94 Australian dollars. (stuart.condie@wsj.com)

0235 GMT - Ramelius Resources' FY 2027 and 2028 production outlook is moderately below expectations, says Euroz Hartleys. However, that is offset by lower-than-expected operating costs "and an exceptional forward outlook in FY29 and FY30," the broker says. Rising free cash flow and falling capital expenditure should bolster capacity for additional dividends and share buybacks, says Euroz Hartleys. "We continue to be confident that RMS' superior cash flow outlook against its peers will result in a share price re-rate over FY27 as investors start to look toward future cashflows," it says. The broker keeps a buy recommendation and A$5.04/share price target. The stock is up 6.4% at A$3.81. (rhiannon.hoyle@wsj.com; @RhiannonHoyle)

0221 GMT - MA Moelis Australia wonders whether FireFly Metals investors will have the patience and risk appetite to hold the stock when it is "already reflecting much of the intrinsic value of the business." MA says it has high conviction in the company's Green Bay copper-gold project, which it thinks will be comfortably funded. But it would "like to see significantly more upside between our price target and where the equity is trading as a reward for both the duration and complication of bringing Green Bay back to life," it says. MA has a hold rating and a A$1.80/share target on FireFly. Shares are down 5.4% at A$1.6975. (rhiannon.hoyle@wsj.com; @RhiannonHoyle)

0137 GMT - Pantoro Gold's output rate puts it on track to produce 21,000-22,000 oz of gold in 1Q FY 2027, says MA Moelis Australia. That would be a marked improvement from the two quarters immediately preceding, when it produced roughly 17,000-18,000 oz each time, it says. As of Sept. 19, Pantoro produced 19,130 oz--in line with MA's forecast for the entire quarter. "Production so far suggests the company is trending well towards its guidance--albeit it remains early in the year," says MA. Pantoro has forecast FY 2027 gold output of 90,000-105,000 oz, and says only 40%-45% of annual output will happen in 1H. MA has a buy rating and target price of 3.65 Australian dollars a share on the miner. The stock is up 3.3% at A$2.86. (rhiannon.hoyle@wsj.com; @RhiannonHoyle)

2359 GMT - Ramelius Resources' new FY 2030 production target is, at its midpoint, 12% above consensus, says RBC Capital Markets. The miner's FY 2030 all-in sustaining cost guidance, also at its midpoint, is 4% below consensus, the broker says. In the nearer term, Ramelius's FY27 production and AISC guidance are broadly in line with expectations, it says. RBC has a sector perform rating and 3.70 Australian dollar share target on Ramelius. The stock ended Friday at A$3.58.